At a glance
- Originator Mitsubishi Pharma Corporation
- Class Antibacterials; Quinolones
- Mechanism of Action Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Helicobacter infections
Most Recent Events
- 06 Apr 2000 Yoshitomi is now called Welfide Corporation
- 09 Oct 1998 New profile
- 09 Oct 1998 Preclinical development for Helicobacter infections in Japan (Unknown route)